Merlin Cut Time, Complications, and Costs
It has certainly been an interesting time for the pharmaceutical industry. As we're starting to transition towards a “new normal”, the pandemic has made us think about how we approach R&D, whilst assessing risks.
Big Change for the Industry
We have seen powder molecules taken to clinical trial with unprecedented speed. This is in contrast to previous industry delays, resulting in a timeframe years longer than what is currently being experienced.
This has only been possible with global information sharing, flexible and pragmatic regulators, and a desire to improve the health outcomes of our most vulnerable.